Congressional committee investigates former NCI Director Richard Klausner’s role in $40 million Harvard contract; NIH begins internal review. Klausner: investigation casts “strange innuendoes.” Text of committee’s letter.
Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.
NCI program announcement available, contract awards listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care









